Keqian Biology(SH:688526)2022-04-18 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥202,659,616.48, representing a decrease of 36.46% compared to the same period last year[6] - Net profit attributable to shareholders was ¥90,765,951.22, down 46.28% year-over-year[6] - The net profit after deducting non-recurring gains and losses was ¥86,898,785.47, reflecting a decline of 48.01%[6] - Basic and diluted earnings per share were both ¥0.20, down 44.44% compared to the previous year[9] - The total comprehensive income attributable to the parent company for Q1 2022 was CNY 90,765,951.22, a decrease from CNY 168,950,625.50 in Q1 2021, representing a decline of approximately 46.3%[41] - The net profit for Q1 2022 was ¥91,165,591.78, down from ¥168,328,095.29 in Q1 2021, representing a decline of approximately 46%[55] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 57.29% to ¥106,372,713.71 due to reduced sales[6] - The net cash flow from operating activities for Q1 2022 was ¥117,957,462.19, a decrease of 52.7% compared to ¥248,853,850.18 in Q1 2021[57] - Cash received from the sale of goods and services in Q1 2022 was CNY 280,089,466.12, a decrease of 30.9% compared to CNY 406,470,039.22 in Q1 2021[41] - The company's cash and cash equivalents were CNY 546,907,502.65, slightly down from CNY 555,361,532.31 in the previous year, indicating a decrease of about 1%[28] - The total cash and cash equivalents at the end of Q1 2022 were CNY 536,416,247.50, down from CNY 684,752,837.04 at the end of Q1 2021, reflecting a decrease of approximately 21.7%[46] - The net cash outflow from investing activities for Q1 2022 was CNY -92,065,332.12, compared to CNY -5,345,327.22 in Q1 2021, indicating a significant increase in investment expenditures[43] Research and Development - Research and development expenses totaled ¥23,935,906.03, an increase of 13.77% year-over-year, accounting for 11.81% of operating revenue, up 5.21 percentage points[9] - The company is actively engaged in the research and development of various vaccines, including a new vaccine for African swine fever, with a registered amount of CNY 557,518.72[23] - The company has multiple ongoing laboratory studies, including a rabies vaccine with a registered amount of CNY 969,994.79[27] - Research and development expenses for Q1 2022 were CNY 23,935,906.03, up from CNY 21,038,754.76 in Q1 2021, indicating a focus on innovation[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,814,661,793.00, a 2.40% increase from the end of the previous year[9] - Total liabilities amounted to CNY 569,925,817.46, slightly down from CNY 571,411,688.95 in the previous period[33] - The total assets increased to ¥3,790,544,740.08 in Q1 2022, up from ¥3,657,708,372.89 in Q1 2021, marking an increase of approximately 4%[51] - The total liabilities rose to ¥547,692,104.91 in Q1 2022, compared to ¥506,021,329.50 in Q1 2021, indicating an increase of about 8%[51] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,510[17] - The largest shareholder, Wuhan Huazhong Agricultural Assets Management Co., Ltd., holds 78,004,310 shares, accounting for 16.77% of the total shares[17] - The top ten shareholders include Chen Huan Chun and Jin Mei Lin, who hold 15.23% and 7.89% of shares, respectively[17] - The company has no pledged, marked, or frozen shares among the top ten shareholders[17] Market Conditions - The decline in operating revenue was attributed to a decrease in vaccine procurement willingness among farmers due to market conditions[14]